Transcode Therapeutics Ownership
| RNAZ Stock | USD 1.12 0.35 45.45% |
Transcode |
Transcode Stock Ownership Analysis
About 22.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.47. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Transcode Therapeutics recorded earning per share (EPS) of 5571.72. The entity had not issued any dividends in recent years. The firm had 1:33 split on the 4th of December 2024. TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. The company was incorporated in 2016 and is based in Boston, Massachusetts. Transcode Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To find out more about Transcode Therapeutics contact Thomas MBA at 857 837 3099 or learn more at https://www.transcodetherapeutics.com.Besides selling stocks to institutional investors, Transcode Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Transcode Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Transcode Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Transcode Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 5.0% of Transcode Therapeutics are currently held by insiders. Unlike Transcode Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Transcode Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Transcode Therapeutics' insider trades
Transcode Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Transcode Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Transcode Therapeutics backward and forwards among themselves. Transcode Therapeutics' institutional investor refers to the entity that pools money to purchase Transcode Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | First Personal Financial Services Inc | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-12-31 | 8.7 K | Tower Research Capital Llc | 2024-12-31 | 926 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 304 | Bank Of America Corp | 2024-12-31 | 4.0 | Captrust Financial Advisors | 2024-12-31 | 0.0 | Susquehanna International Group, Llp | 2024-09-30 | 0.0 |
Transcode Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Transcode Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Transcode Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Transcode Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Transcode Therapeutics Outstanding Bonds
Transcode Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Transcode Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Transcode bonds can be classified according to their maturity, which is the date when Transcode Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| TRANSCANADA PIPELINES LTD Corp BondUS893526DF78 | View | |
| TRANSCANADA PIPELINES LTD Corp BondUS893526DJ90 | View | |
| TRANSATLANTIC HLDGS INC Corp BondUS893521AB05 | View | |
| TRANSCONTINENTAL GAS PIPE Corp BondUS893574AB92 | View | |
| TRANSCONTINENTAL GAS PIPE Corp BondUS893574AH62 | View | |
| US893574AF07 Corp BondUS893574AF07 | View | |
| TRPCN 55 15 SEP 79 Corp BondUS89356BAE83 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.